What is HC Wainwright's Forecast for SNTI Q3 Earnings?

Key Points

• HC Wainwright expects Senti Biosciences to report a Q3 2025 earnings per share of ($0.59) and maintains a "Buy" rating with a price target of $12.00.
• Senti Biosciences stock recently surged 11.1% and has a current market cap of $60.43 million, with a price-to-earnings ratio of -0.26.
• Institutional investors have significantly increased their holdings in Senti Biosciences, owning approximately 25.73% of the company's stock.

Senti Biosciences, Inc. (NASDAQ:SNTI - Free Report) - Analysts at HC Wainwright issued their Q3 2025 earnings estimates for shares of Senti Biosciences in a research report issued on Tuesday, October 14th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.59) for the quarter. HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Senti Biosciences' current full-year earnings is ($14.54) per share. HC Wainwright also issued estimates for Senti Biosciences' Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($2.73) EPS, FY2026 earnings at ($1.29) EPS, FY2027 earnings at ($0.93) EPS, FY2028 earnings at ($0.60) EPS and FY2029 earnings at ($0.47) EPS.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Senti Biosciences in a report on Wednesday, October 8th. Wall Street Zen raised shares of Senti Biosciences from a "sell" rating to a "hold" rating in a report on Monday, August 18th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $12.00 target price on shares of Senti Biosciences in a report on Friday, August 8th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $9.67.

Senti Biosciences Stock Up 11.1%

Senti Biosciences stock opened at $2.31 on Thursday. Senti Biosciences has a 52-week low of $1.26 and a 52-week high of $16.94. The firm has a market capitalization of $60.43 million, a price-to-earnings ratio of -0.26 and a beta of 2.04. The company has a fifty day simple moving average of $1.53 and a 200-day simple moving average of $2.38.

Senti Biosciences (NASDAQ:SNTI - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.02. The business had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.30 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in shares of Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company's stock valued at $311,000 after acquiring an additional 117,588 shares during the last quarter. Heights Capital Management Inc. acquired a new position in shares of Senti Biosciences during the 1st quarter valued at about $2,520,000. Nantahala Capital Management LLC purchased a new stake in Senti Biosciences in the 1st quarter valued at about $2,984,000. Finally, Armistice Capital LLC purchased a new stake in Senti Biosciences in the 2nd quarter valued at about $1,883,000. Institutional investors and hedge funds own 25.73% of the company's stock.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.